Reckitt bolsters US presence with new Wilson OTC facility
In This Article:
UK-based consumer goods company Reckitt Benckiser plans to establish a new over-the-counter (OTC) pharmaceutical manufacturing site in North Carolina, US.
Reckitt has acquired a 310,000sq ft pharmaceutical facility in the city of Wilson and is investing £155m ($200m) to equip it for “state-of-the-art manufacturing”. The site will be used to boost the production of the company's Mucinex cold and flu relief to meet increased demand in the US.
Harald Emberger, chief supply officer at Reckitt, said: “Mucinex is our best OTC product in the US and the best global cough and decongestant medicine, so we are taking action to expand access to our products and build a more resilient supply chain. The Wilson facility will greatly increase our Mucinex production capacity, localise more manufacturing and enable us to better serve our customers and consumers.”
The increased demand for Mucinex is linked in part to a change in the seasonality and an increase in the intensity of cold and flu season – both due to the impact of the Covid-19 pandemic.
Reckitt says that the facility will have the capabilities to support other of its products in the future, including Move Free and Biofreeze. It also notes notes that, in addition to creating hundreds of new factory jobs, the facility will support local roles in construction, engineering and transportation.
Reckitt operates across Asia-Pacific, Europe, the Americas, the Middle East and Africa. It has around 42,000 employees globally. Earlier this year in June, it announced a new $41.7m R&D facility in Shanghai, China.
"Reckitt bolsters US presence with new Wilson OTC facility" was originally created and published by Investment Monitor, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.